Ljungberg B, Albiges L, Abu-Ghanem Y et al (2022) European Association of Urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol 82:399–410

Article  PubMed  Google Scholar 

Rathmell WK, Rumble RB, Van Veldhuizen PJ et al (2022) Management of metastatic clear cell renal cell carcinoma: ASCO guideline. J Clin Oncol 40:2957–2995

Article  CAS  PubMed  Google Scholar 

Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803–1813

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choueiri TK, Powles T, Burotto M et al (2021) Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 384:829–841

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motzer R, Alekseev B, Rha SY et al (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384:1289–1300

Article  CAS  PubMed  Google Scholar 

Motzer RJ, Robbins PB, Powles T et al (2020) Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN renal 101 trial. Nat Med 26:1733–1741

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378:1277–1290

Article  CAS  PubMed  PubMed Central  Google Scholar 

Powles T, Plimack ER, Soulières D et al (2020) Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol 21:1563–1573

Article  CAS  PubMed  Google Scholar 

Ishihara H, Tachibana H, Takagi T et al (2019) Predictive impact of peripheral blood markers and C-reactive protein in nivolumab therapy for metastatic renal cell carcinoma. Target Oncol 14:453–463

Article  PubMed  Google Scholar 

Semeniuk-Wojtaś A, Lubas A, Stec R et al (2018) Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and C-reactive protein as new and simple prognostic factors in patients with metastatic renal cell cancer treated with tyrosine kinase inhibitors: a systemic review and meta-analysis. Clin Genitourin Cancer 16:e685–e693

Article  PubMed  Google Scholar 

Ito K, Masunaga A, Tanaka N et al (2019) Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma. Jpn J Clin Oncol 49:69–76

Article  PubMed  Google Scholar 

Yasuda Y, Saito K, Yuasa T et al (2017) Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Int J Clin Oncol 22:1081–1086

Article  CAS  PubMed  Google Scholar 

Washino S, Takeshita H, Inoue M et al (2021) Real-world incidence of immune-related adverse events associated with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma: a retrospective observational study. J Clin Med 10:4767

Article  CAS  PubMed  PubMed Central  Google Scholar 

Izumi K, Inoue M, Washino S et al (2023) Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: real-world data from a Japanese multicenter retrospective study. Int J Urol 30:714–721

Article  CAS  PubMed  Google Scholar 

Washino S, Shirotake S, Takeshita H et al (2023) Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis. Int J Clin Oncol 28:1651–1658

Article  CAS  PubMed  Google Scholar 

Heng DY, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27:5794–5799

Article  CAS  PubMed  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

Article  CAS  PubMed  Google Scholar 

Diakos CI, Charles KA, McMillan DC et al (2014) Cancer-related inflammation and treatment effectiveness. Lancet Oncol 15:e493–e503

Article  PubMed  Google Scholar 

Iinuma K, Enomoto T, Kawada K et al (2021) Utility of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune inflammation index as prognostic, predictive biomarkers in patients with metastatic renal cell carcinoma treated with nivolumab and ipilimumab. J Clin Med 10(22):5325

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rebuzzi SE, Signori A, Buti S et al (2022) Validation of the meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program. ESMO Open 7:100634

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saito K, Kihara K (2011) C-reactive protein as a biomarker for urological cancers. Nat Rev Urol 8:659–666

Article  CAS  PubMed  Google Scholar 

Nakayama T, Saito K, Kumagai J et al (2018) Higher serum C-reactive protein level represents the immunosuppressive tumor microenvironment in patients with clear cell renal cell carcinoma. Clin Genitourin Cancer 16:e1151–e1158

Article  PubMed  Google Scholar